Pharmacokinetic properties and bioequivalence of two compound formulations of 1500 mg ampicillin (1167 mg)/ probenecid (333 mg): A randomized-sequence, single-dose, open-label, two-period crossover study in healthy Chinese male volunteers

Clinical Therapeutics

Volumn 32, Issue 3, 2010, Pages 597-606

  Wu, Huizhe ^a   Liu, Mingyan ^a   Wang, Shuang ^a   Feng, Wanyu ^a   Yao, Weifan ^a   Zhao, Haishan ^a   Wei, Minjie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Ampicillin; Bioequivalence; HPLC; Pharmacokinetics; Probenecid

Indexed keywords

AMPICILLIN; AMPICILLIN PLUS PROBENECID; PROBENECID; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG TRANSFORMATION; ENTERITIS; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH DISEASE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOLUNTEER; VOMITING;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; AMPICILLIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CAPSULES; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG SYNERGISM; HUMANS; MALE; PROBENECID; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 77951932609     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.03.017     Document Type: Article

References (19)

1. Katzung BG Basic and Clinical Pharmacology 1996, Lange Medical Publications, Los Altos, Calif. 2nd ed.
2. Hardman JG, Limbird LE, Goodman Gilman A Goodman & Oilman's The Pharmacological Basis of Therapeutics 2001, McGraw-Hill Inc, New York, NY. 10th ed.
3. Schumacher I, Margalit R Liposome-encapsulated ampicillin: Physiochemical and antibacterial properties. J Pharm Sci. 1997, 86:635-641.
4. Lafforgue G, Arellano C, Vachoux C, et al. Oral absorption of ampicillin: Role of paracellular route vs. PepT1 transporter. Fundam Clin Pharmacol. 2008, 22:189-201.
5. DiPiro JT, Albert RL Pharmacotherapy: A Pathophysiologic Approach 2002, McGraw-Hill Inc, New York, NY. 5th ed.
6. Gehring R, van der Merwe D, Pierce AN, et al. Multivariate meta-analysis of pharmacokinetic studies of ampicillin trihydrate in cattle. Am J Vet Res. 2005, 66:108-112.
7. Kampffmeyer HG, Hartmann I, Metz H, et al. Serum concentrations of ampicillin and probenecid and ampicillin excretion after repeated oral administration of a pivampicillinprobenecid salt (MK-356). Eur J Clin Pharmacol. 1975, 9:125-129.
8. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects World Medical Association (WMA), Accessed August 16, 2006. http://www.wma.net/en/30publications/10policies/b3/index.html.
9. Good Clinical Practice Guideline State Food and Drug Administration, Accessed August 6, 2003. http://www.sda.gov.cn/WS01/CL0053/24473.html.
10. Xu Y, Sun Z Medical Statistics 2004, 343-344. Higher Education Press, Beijing, China, Appendix 15. 2nd ed.
11. Provisions for Drug State Food and Drug Administration, Accessed July 10, 2007. http://www.sda.gov.cn/WS01/CL0053/24529.html.
12. Yinglan Z, Juying H, Songqing L, et al. Content determination of ampicillin and probenecid in ampicillin/probenecid capsules by HPLC. China Pharmaceuticals. 2006, 15:27-29.
13. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations US Department of Health and Human Services, Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed November 8, 2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
14. In vivo bioequivalence guidance. Pharmacopeial Forum. 1993, 19:6501-6508. US Food and Drug Administration.
15. Guidance for Industry: Statistical approaches to establishing bioequivalence US Department of Health and Human Services, Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed March 3, 2010. http://www.scribd.com/doc/4204696/Statistical-Approaches-to-Establishing-Bioequivalence.
16. Instruction for the In Vivo Bioequivalence Study Protocol Development US Food and Drug Administration, Accessed September 14, 2008. http://www.app1.fda.moph.go.th/drug/zone_bioequivalence/files/be_inhuman.pdf.
17. Williams RL, Chen ML, Hauck WW Equivalence approaches. Clin Pharmacol Ther. 2002, 72:229-237.
18. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Bio-pharm. 1987, 15:657-680.
19. Anderson S, Hauck WW A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Commun Stat Theory Methods. 1983, 12:2663-2692.